Psoriasis vulgaris

L12_PSORI_VULG

psoriasis: An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.

Endpoint definition

FinnGen phenotype data

321302 individuals

diagram downward connector

Apply sex-specific rule None

321302

diagram downward connector

Check conditions None

321302

diagram downward connector
diagram bullet

Filter registries

Hospital Discharge: ICD-10 L40.0
Hospital discharge: ICD-9 6961A
Hospital discharge: ICD-8 $!$
Cause of death: ICD-10 L40.0
Cause of death: ICD-9 6961A
Cause of death: ICD-8 $!$
KELA reimbursements: KELA codes ANY
KELA reimbursements: ICD-10 L40.0

165209

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, ICD version

Look only at ICD versions H.D: 10, 8, 9 ; C.O.D: 10, 8, 9

4496

diagram downward connector

Check minimum number of events None

4496

diagram downward connector

Include endpoints None

4496

diagram downward connector
L12_PSORI_VULG

Extra metadata

Level in the ICD hierarchy 4
First used in FinnGen datafreeze DF2
Parent code in ICD-10 L40
Name in latin Psoriasis vulgaris

Summary Statistics

Key figures

All Female Male
Number of individuals 4321 2074 2247
Unadjusted prevalence (%) 1.40 1.20 1.66
Mean age at first event (years) 50.52 48.65 52.25

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.04 2.80 [2.12, 3.71] 5.7e-13 358
15 years 0.01 1.87 [1.45, 2.42] 2.0e-6 191
5 years 0.00 2.76 [2.08, 3.66] 1.8e-12 89
1 year 0.00 3.27 [2.03, 5.26] 1.0e-6 20

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: L12_PSORI_VULG – Psoriasis vulgaris
GWS hits: 18

Survival analyses between endpoints

Plot

before Psoriasis vulgaris
after Psoriasis vulgaris

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Psoriasis vulgaris